Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On June 30, 2009, the Board of Directors of GeneLink, Inc. appointed James Antal to the Board of Directors. Mr. Antal, 58, will serve as Chairman of the Audit Committee. Mr. Antal qualifies as an independent audit committee financial expert. Mr. Antal is a member of the board of directors of Cleveland Biolabs, Inc. (Nasdaq:CBLI), a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications. He has served since 2006 and is presently chair of the Audit Committee and member of the Compensation Committee. Mr. Antal served as Chief Financial Officer of Experian Plc from 1996 to 2001 and as Chief Investment Officer of Experian from 2001 to 2002. Experian is a leading global provider of consumer and business credit information, direct marketing information services, and integrated customer relationship management processes. He also served on the Board of Directors of First American Real Estate Solutions, an Experian joint venture with First American Financial Corp. Mr. Antal earned a Bachelor of Science degree in Business Administration with an Accounting major from The Ohio State University in 1973. He became a Certified Public Accountant (Ohio) in 1975. Starting in 2002, Mr. Antal served as an advisor to the board of directors for Plexus Vaccine, Inc., a biotech company, until it was acquired by SIGA Technologies in 2004. In December 2004, he joined the SIGA board of directors, and also currently serves on its audit and corporate governance committees. From May 2004 to August 2005, he was engaged as the Chief Financial Advisor to the Black Mountain Gold Coffee Co. In July 2005, he joined Pathway Data Inc, a privately held company engaged in consumer credit notification and identity theft assistance services, as its part-time Chief Financial Officer.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits

99.1 Press Release dated July 6, 2009 of GeneLink, Inc.

- 2 -

---

Table of Contents

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GeneLink, Inc. (Registrant)

By: /s/ Monte E. Taylor, Jr.
Monte E. Taylor, Jr.
Chief Executive Officer

Dated: July 6, 2009

- 3 -

---

Table of Contents